DelistingJun 10, 2026, 05:31 PM
BIO-key Receives Nasdaq Delisting Notice; Hearing Set for June 16
AI Summary
BIO-key International received a notice from Nasdaq on June 5, 2026, stating that its failure to file the Quarterly Report on Form 10-Q for the period ended March 31, 2026, is an additional basis for delisting its common stock. The Nasdaq Hearing Panel will consider this non-compliance during a hearing scheduled for June 16, 2026, which was previously set to address the company's appeal of Nasdaq's May 6, 2026, suspension determination. The company is actively working to regain compliance, though there is no assurance of continued listing.
Key Highlights
- BIO-key International received a Nasdaq notice on June 5, 2026, for failing to file its Q1 2026 Form 10-Q.
- This failure serves as an additional basis for delisting under Nasdaq Listing Rule 5250(c)(1).
- The Nasdaq Hearing Panel will consider this non-compliance in its determination regarding continued listing.
- The company previously appealed Nasdaq's May 6, 2026, determination to suspend trading.
- A hearing with the Nasdaq Hearing Panel is scheduled for June 16, 2026.
- BIO-key is taking measures to regain compliance with the Periodic Report Rule and remain listed.
Price Impact
More from BKYI